Skip to main content

Table 3 Time to tumor progression at the end of each year during follow-up

From: Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry

Year Patients with progression Patients censored Product-limit survival estimates 95%-confidence interval of survival estimates Patients left
Lower limit Upper limit
1 and 2 0 0 100.0%    268
3 72 29 71.6% 65.6% 76.8% 167
4 29 39 57.1% 50.4% 63.3% 99
5 15 29 47.1% 39.9% 54.1% 55
6 3 22 43.9% 36.2% 51.3% 30
7 2 15 40.5% 32.1% 48.7% 13
8 1 4 36.5% 26.0% 47.0% 8
9 1 3 29.2% 15.1% 44.8% 4
10 3 1 0.0% - - 0